Search results
Results from the WOW.Com Content Network
The findings on marijuana's relationship to depressive disorder are scattered, showing that cannabis use has benefits, but can also be detrimental to overall mental health. However, sufficient evidence exists showing reductions in cannabis use improve anxiety, depression, and sleep quality. [54]
Cannabis use disorder is defined in the fifth revision of the Diagnostic and Statistical Manual of Mental Disorders as a condition requiring treatment. [107] Several drugs have been investigated in an attempt to ameliorate the symptoms of stopping cannabis use. Such drugs include bupropion, divalproex, nefazodone, lofexidine, and dronabinol.
Legal cannabis (marijuana) product. Overconsumption and reliance could lead to cannabis-induced amotivational syndrome. The term amotivational syndrome was first devised to understand and explain the diminished drive and desire to work or compete among the population of youth who are frequent consumers of cannabis and has since been researched through various methodological studies with this ...
Weed affects your ability to make decisions, control emotions, remember important data, plan, organize and solve problems, a new study found, and that impact may last well past your initial high.
Daily marijuana use among young adults has risen to record highs, with more than 1 in 10 of young adults ages 19-30 now reporting daily use, and almost half reporting use within the last year ...
The Centers for Disease Control and Prevention notes that marijuana can absolutely affect a person's brain health — causing changes in memory, attention, learning ability and even mood —and ...
For the treatment of the withdrawal/negative affect symptom domain of cannabis use disorder, medications may work by alleviating restlessness, irritable or depressed mood, anxiety, and insomnia. [58] Bupropion , which is a norepinephrine–dopamine reuptake inhibitor , has been studied for the treatment of withdrawal with largely poor results ...
Canadian researchers examined the health records of more than 12 million people living in Ontario between 2008 and 2019 who had no record of an anxiety disorder, or of receiving treatment for one.